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ABSTRACT
Introduction: Gait is inefficient in children with
cerebral palsy, particularly as they transition to
adolescence. Gait inefficiency may be associated with
declines in gross motor function and participation
among adolescents with cerebral palsy. Resistance
training may improve gait efficiency through a number
of biomechanical and neural mechanisms. The aim of
the Strength Training for Adolescents with cerebral
palsy (STAR) trial is to evaluate the effect of resistance
training on gait efficiency, activity and participation in
adolescents with cerebral palsy. We also aim to
determine the biomechanical and neural adaptations
that occur following resistance training and evaluate
the feasibility and acceptability of such an intervention
for adolescents with cerebral palsy.
Methods and analysis: 60 adolescents (Gross Motor
Function Classification System level I–III) will be
randomised to a 10-week resistance training group or a
usual care control group according to a computer-
generated random schedule. The primary outcome is
gait efficiency. Secondary outcomes are habitual physical
activity, participation, muscle–tendon mechanics and
gross motor function. General linear models will be used
to evaluate differences in continuous data between the
resistance training and usual care groups at 10 and
22 weeks, respectively. A process evaluation will be
conducted alongside the intervention. Fidelity of the
resistance training programme to trial protocol will be
quantified by observations of exercise sessions.
Semistructured interviews will be conducted with
participants and physiotherapists following the resistance
training programme to determine feasibility and
acceptability of the programme.
Ethics and dissemination: This trial has ethical
approval from Brunel University London’s Department
of Clinical Sciences’ Research Ethics Committee and
the National Research Ethics Service (NRES)
Committee London—Surrey Borders. The results of the
trial will be submitted for publication in academic
journals, presented at conferences and distributed to
adolescents, families and healthcare professionals
through the media with the assistance of the STAR
advisory group.
Trial registration number: ISRCTN90378161;
Pre-results.
INTRODUCTION
Cerebral palsy (CP) is a neurodevelopmental
condition that begins in childhood and has a
life-long impact on the individual and health-
care system. Although adults with
mild-to-moderate CP have a relatively normal
life expectancy,1 many experience deterior-
ation in walking function between 20 and
40 years of age.2–4 This can lead to physical
inactivity,5 6 which in turn may result in
increased risk of developing cardiovascular
disease,5 7–9 and limit participation and
social integration in the home and commu-
nity. The oxygen cost of walking, which is
Strengths and limitations of this study
▪ The results of this trial will contribute to our
understanding of the effect of resistance training
on muscle–tendon mechanics in adolescents
with cerebral palsy (CP), therefore bridging the
gap between basic science and clinical efficacy.
▪ The findings of the process evaluation will
improve the normalisation of the intervention
into routine clinical practice by identifying indi-
vidual, societal and contextual barriers to suc-
cessful implementation of resistance training
among adolescents with CP.
▪ This is an efficacy study and therefore the results
should not be considered conclusive.
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often used as a measure of gait efﬁciency,10 is high
among children and adolescents with CP in comparison
to their peers with typical development.11–13 Gait inefﬁ-
ciency may contribute to the negative cycle of physical
inactivity, deterioration in walking function and physical
de-conditioning.14 Reduced gait efﬁciency is also nega-
tively associated with gross motor function and participa-
tion in mobility-related activities,15 and may cause
fatigue, which further exacerbates deterioration in
walking function.3 As gait is most inefﬁcient at age
12 years in CP and gross motor function skills deterior-
ate shortly afterwards,16 targeted interventions during
adolescence could disrupt this negative cycle.
Resistance training, which is commonly used for
people with CP, has the potential to improve gait efﬁ-
ciency through a number of biomechanical and neural
mechanisms. First, co-contraction of antagonistic muscles
is exacerbated in CP17–19 and contributes to gait inefﬁ-
ciency.20 Studies involving children with typical develop-
ment indicate that early resistance training-induced
strength gains are predominantly neural in nature.21–23 A
study of children with CP suggests that a reduction in
antagonistic co-contraction may be a partial contribu-
tor.24 Second, excessive lengthening of the muscle fasci-
cles during the single stance phase of walking could
contribute to the increased energy cost of walking
among people with CP. In typically developed gait it has
been shown that in spite of signiﬁcant length changes of
the plantarﬂexor muscle–tendon unit as a whole, triceps
surae muscle fascicles operate almost isometrically
during the early to mid-stance phase of walking.25 In the
subsequent propulsive phase, the fascicles shorten at vel-
ocities associated with high efﬁciency.26–28 This has been
proposed to be an energy-saving mechanism during
walking.29 Pilot data suggest that in children with CP and
equinus gait, the fascicles of the gastrocnemius muscle
lengthen during the single support phase of walking,30 31
rather than act isometrically, potentially due to the
muscle’s inability to resist the tensile forces in stance.
Since eccentric muscle contractions are metabolically
less efﬁcient than isometric contractions,32 this may con-
tribute to walking inefﬁciency in people with CP. An
increase in the volume and strength of these muscles
due to resistance training may have a positive effect on
oxygen cost by enabling fascicles to work more isometric-
ally during gait. Finally, the degree to which the muscle
shortens during dynamic contractions is governed by the
elastic properties of muscles and tendons (ie, stiffness).
It has been previously demonstrated that children with
CP have an increased passive stiffness and disproportion-
ally long Achilles tendon.33 34 This may reduce the
ability of the muscle to generate adequate force in the
propulsive phase of gait, as fascicles are not operating at
optimum lengths or velocities. Resistance training has
been shown to increase tendon stiffness by up to 25% in
children with typical development,35 thus demonstrating
the potential to affect the ratio of muscle to tendon
stiffness in CP in a way that promotes a more efﬁcient
muscle–tendon interaction and muscle contraction
during gait. Such changes may improve gait efﬁciency in
this population.
Resistance training has been advocated for adolescents
with CP for decades as it may delay the loss of mobility
in adulthood by increasing muscular reserve,36 reduce
the risk of chronic disease such as type II diabetes melli-
tus,37 38 and improve walking function.39 40 However,
current evidence for the use of resistance training to
improve walking function is equivocal41–43 and thus,
clarity is required. The uncertainty regarding the effects
of resistance training on walking function may be due to
a number of shortcomings in current research. First,
many resistance training protocols are of an inadequate
volume, intensity or duration.38 For neural and musculo-
tendinous adaptations to occur, an adequate training
stimulus and duration are required.44 In addition, multi-
joint exercises are often used in resistance training pro-
grammes. As people with CP have severe muscle
weakness, they may compensate with stronger muscles
when performing multijoint exercises.39 40 The efﬁcacy
of resistance training may also vary according to the
muscle group targeted. Resistance training in CP is pri-
marily targeted at the knee extensors39 43 45 despite
muscle deﬁcits being most pronounced at the ankle.46 47
Plantarﬂexor strength is associated with walking function
and step cadence in CP;48 49 and pilot data suggest that
progressive resistance training of the plantarﬂexors
using single-joint exercises improves muscle strength,
muscle volume,50 walking speed and stride length.51
Further, the underlying biomechanical and neural adap-
tations to resistance training are poorly understood in
people with CP. When evaluating a complex interven-
tion, it is imperative that a theoretical understanding of
the likely process of change is developed.52 The paucity
of research into resistance training-induced adaptations
in CP means that current clinical practice is potentially
based on erroneous assumptions.
We hypothesise that training the ankle plantarﬂexors
with progressive resistance training will result in
increases in gait efﬁciency through the biomechanical
and neural adaptations outlined above. The aims of the
Strength Training for Adolescents with CP (STAR) trial
are to (1) evaluate the effect of resistance training of the
ankle plantarﬂexors on gait efﬁciency, activity and par-
ticipation in adolescents with CP, (2) determine the bio-
mechanical and neural adaptations that occur following
resistance training in adolescents with CP and (3) evalu-
ate the feasibility and acceptability of resistance training
for adolescents with CP.
METHODS AND ANALYSIS
Study design
This is a multicentre randomised controlled trial with a
parallel process evaluation (ﬁgure 1). Participants will
be recruited through the National Health Service,
schools and organisations for people with disabilities
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throughout England. Assessments will be conducted at
Brunel University London. Participants will be randomly
assigned to one of two groups (exercise or usual care
control group) in a 1:1 ratio after completing baseline
assessments. Allocation will be performed by an individ-
ual independent to the study according to a computer-
generated random schedule in permuted blocks of two
or four within Gross Motor Function Classiﬁcation
System (GMFCS) level strata (levels I–II and level III).
The allocation of participants to each group within each
stratum will be placed in sequentially numbered,
opaque, sealed envelopes, so that participants and
researchers enrolling participants cannot foresee assign-
ment. All participants will be instructed to continue
their usual physiotherapy and activities, provided it does
not include progressive resistance training. Usual physio-
therapy and participation in physical activities will be
monitored at baseline, 10 and 22 weeks. A usual care
checklist, developed from the results of a national survey
of physiotherapists in the UK regarding usual care for
adolescents with CP, will be used to monitor usual
physiotherapy.
Trial status
At the time of submission of this study protocol, the trial
is ongoing and recruiting participants. Recruitment
began in August 2015 and is expected to end in August
2017.
Participants
Sixty adolescents will be recruited. The inclusion criteria
for the proposed trial are (1) adolescents with spastic
CP aged 10–19 years (amended from 12 to 19 years on
15 February 2016), (2) the ability to walk independently
Figure 1 Experimental design for the STAR trial. STAR, Strength Training for Adolescents with cerebral palsy.
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with or without a mobility aid (ie, GMFCS levels I–III)
and (3) the ability to activate the ankle plantarﬂexors.
Individuals in GMFCS level I are able to walk indoors
and outdoors without assistance and can perform gross
motor skills such as running and jumping, but speed,
balance and coordination are reduced. Those in level II
can also walk indoors and outdoors without assistance,
but have only minimal ability to perform gross motor
skills like running and jumping. Individuals in level III
require a mobility aid to walk independently and may
use wheeled mobility to travel long distances.53
Participants’ ability to activate their plantarﬂexors on
the right and left leg will be assessed using a modiﬁed
version of the Selective Control Assessment of the Lower
Extremity (SCALE).54 Participants will be asked to dorsi-
ﬂex, plantarﬂex and dorsiﬂex the ankle, while sitting
with their legs over the edge of the examination table
with the knee extended as much as possible, and the
calf supported by the assessor. This assessment will be
performed by the person identifying eligible participants
where possible and also by the research team when the
participant attends the baseline assessment. Participants’
ability to activate their plantarﬂexors will be rated as
‘normal’ if they can achieve 15° of active plantarﬂexion
in the sagittal plane, ‘impaired’ if they achieve <15°
active plantarﬂexion in the sagittal plane or if plantar-
ﬂexion is accompanied by ankle inversion, ‘no active
movement’ if they do not achieve active plantarﬂexion
at the ankle but the plantarﬂexors are activated as deter-
mined by palpation, and ‘unable’ if the plantarﬂexors
are not activated as determined by palpation.
Adolescents who are unable to activate their plantarﬂex-
ors will be excluded from participating in the study.
Exclusion criteria are (1) orthopaedic surgery of the
lower extremities in the past 12 months, (2) botulinum
toxin type A (Botox) injections in the past 6 months, (3)
serial casting in the past 6 months and (4) insufﬁcient
cognitive understanding to comply with the assessment
procedures and training programme.
Resistance training intervention
The progressive resistance training intervention is based
on current guidelines for youth resistance training.44
Adolescents in the resistance training group will partici-
pate in 30 sessions of progressive resistance training over
10 weeks; 10 supervised group sessions will be carried
out at participants’ local physiotherapy department or
gym and 20 sessions will be carried out at participants’
homes. There will be at least 24 hours between each
session. Participants will complete a physical activity
readiness questionnaire prior to participation in resist-
ance training. Single-joint plantarﬂexor exercises will be
prescribed based on individual strength capacities to
ensure the participant can perform a minimum of
6 repetitions and no more than 15 repetitions, that is,
6–15 repetition maximum (RM) which equates to
∼50–85% of 1 RM, in line with current guidelines.44
Each participant will be familiarised with the exercises
and taught the correct technique prior to starting the
programme. Participants will be provided with an OMNI
perceived exertion scale at their ﬁrst appointment to
monitor perceived intensity. The physiotherapist deliver-
ing the programme will prescribe at least one of the fol-
lowing exercises each week depending on the
adolescent’s individual capacity: (1) seated straight knee
calf press against resistance band (TheraBand, Hygenic
Corporation), (2) seated straight knee calf press with a
leg press machine, (3) standing calf raises against body
weight with or without additional resistance and (4)
standing calf raises in a hack squat machine (table 1).
For all exercises, participants will be instructed to keep
the knee joint as straight as possible to ensure activation
of all triceps surae muscles55–57 and perform the exer-
cise through full available range of ankle movement
where possible.
A periodised progressive resistance training pro-
gramme will be used to ensure continued adaptation
throughout the 10 weeks (table 2). Exercises will be
performed at moderate velocity, that is, 1–2 s concentric,
Table 1 Description of plantarflexor exercises performed by adolescents in intervention group
Exercise Starting position
Resistance added in
group session
Resistance added
in home session
Seated straight knee calf
press against resistance
band
Long sitting with knee extended; ankle in
dorsiflexion; band placed around the ball of the
foot and both ends of the band held by the
participant
Resistance band of
varying resistance
Resistance band of
varying resistance
Standing straight knee
calf raise
Standing with knee extended; ankle in
dorsiflexion; ball of foot on step
Body weight/weighted
vest/ankle weights
Body weight/
weighted vest/ankle
weights
Standing straight knee
calf raise with hack squat
machine
Standing in hack squat machine with knee
extended; ankle in dorsiflexion; foot flat on
footplate
Free weights added
to hack squat
machine
Not completed at
home
Seated straight knee calf
press with leg press
machine
Sitting in leg press with knee extended; ankle in
dorsiflexion; foot on footplate
Free weights added
to leg press machine
Not completed at
home
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1–2 s eccentric. A rest period of at least 2 minutes will be
allowed between each set.
Load will be added to each prescribed exercise incre-
mentally at every supervised session to ensure that the
participant can complete the prescribed number of
repetitions in each set to fatigue. For example, in week
8, the participant’s eight RM will be determined at the
start of the supervised session for each prescribed exer-
cise by adding load to the exercise, so that the partici-
pant performs eight repetitions to fatigue in each set.
Fatigue will be indicated by participants’ refusal to com-
plete another repetition, an inability to perform another
full repetition, or improper form that results in the plan-
tarﬂexors not being activated. The load may be adjusted
during the supervised session depending on the indivi-
dual’s capacity to ensure that they are reaching fatigue
during each set.
For the seated straight knee calf press against resist-
ance band, the band will be placed around the ball of
the foot (see online supplementary ﬁle 1). The length
of the resistance band and the position of the partici-
pants’ hands when holding the band will be kept con-
stant during this exercise. Participants will plantarﬂex
at the ankle and push against the resistance band.
When a participant can complete more than the pre-
scribed number of repetitions, they will progress to a
stiffer resistance band until they are able to progress
to a different exercise. The stiffness of the resistance
band increases according to the colour of the band,
from least resistance to most resistance as follows:
yellow, red, green, blue, black, silver, gold. For the
standing calf raise exercise, participants will be
instructed to raise and lower their body using their
calf muscle. If necessary, they will be allowed to hold
onto a chair for balance (see online supplementary
ﬁle 2). Participants may also complete standing calf
raises using a hack squat machine in the group session
(see online supplementary ﬁle 3). For the seated
straight knee calf press with the leg press machine,
participants will be instructed to push against the foot-
plate with the ball of their foot (see online
supplementary ﬁle 4).
Participants will not perform all four exercises at each
session. Instead, they will perform a combination of one
or more exercises, depending on their individual
strength capacity each week. Each participant will
perform the prescribed exercise(s) until they complete
the required number of sets and repetitions of plantar-
ﬂexor exercises on each leg. For example, in week 1, a
participant may be prescribed four sets of 12 repetitions
of seated straight knee calf presses against a resistance
band on each leg. In week 2, if they are able to perform
>12 repetitions against the strongest resistance band they
may be prescribed four sets of 12 repetitions of standing
calf raises on each leg. They could also be prescribed
two sets of 12 repetitions of standing calf raises and two
sets of 12 repetitions of the seated straight knee calf
press with the leg press machine, on each leg. The
number and type of exercises prescribed will be at the
discretion of the physiotherapist provided they adhere to
the prescribed repetitions, sets and intensity for a given
week.
Unilateral exercises will be performed where possible.
If a participant is unable to perform unilateral exercises,
they will perform bilateral exercises initially until they
are able to progress to unilateral exercises.
Each supervised session will be managed by a physio-
therapist who has received training in delivering the
resistance training programme. All physiotherapists deli-
vering the intervention will receive a standardised clin-
ician manual and on-site training. Participants are
advised to perform a 5–10 min aerobic warm-up of lower
limb aerobic exercise and a 5 min cool-down consisting
of lower limb aerobic exercise and plantarﬂexor
stretches at each session. At the start of each session, the
physiotherapist will ask participants if they experienced
any adverse events since the last supervised session and
record reported events. At the end of the class, the
physiotherapist will ask participants if they experienced
any adverse events during the class, which will also be
recorded. At the end of the supervised session, the
physiotherapist will outline the exercises each partici-
pant has to complete at home and provide any equip-
ment required to complete the exercises. The type of
exercise and amount of load added to the exercise will
be based on the exercise(s) the participant performed
in the supervised session. Participants will be provided
with a paper exercise diary containing photographs of
the prescribed exercises and the prescribed number of
repetitions and sets for each exercise. They will also be
provided with videos on how to perform their home
exercises via a patient support tool (Salaso Health
Solutions, Kerry, Ireland), which they will access through
the website or the application on a smartphone or
tablet.
Outcome measures
Participants in both groups will be tested for the follow-
ing dependent variables at baseline, at 10 weeks (imme-
diately postintervention), and at 22 weeks (12 weeks
postintervention). Attempts will be made to collect all
outcome data for participants who discontinue the
intervention.
Table 2 Periodised progression of resistance exercises
performed by adolescents in intervention group
Weeks Sets Repetitions Intensity Muscle action
1 and 2 4 12 12 RM ECC and CON
3 and 4 6 12 12 RM ECC and CON
5 and 6 6 8 8 RM ECC and CON
7 and 8 8 8 8 RM ECC and CON
9 and 10 8 6 6 RM ECC and CON
CON, concentric; ECC, eccentric; RM, repetition maximum.
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Primary outcome measure
Gait efficiency
Gait efﬁciency will be measured by a blinded assessor
using a protocol outlined by Schwartz.58 Participants’
mass to the nearest 0.1 kg and stature to the nearest
0.1 m will be measured. Oxygen consumption will be
recorded using a portable metabolic system (Cosmed
K5, Rome, Italy) during a 10 min rest period in a semire-
cumbent position and during 6 min of overground
walking at a self-selected speed. Participants’ average
walking speed will be measured in 1 min intervals. Prior
to each test the Cosmed K5 will be calibrated for oxygen
and carbon dioxide concentration and turbine ﬂow
according to the manufacturer’s recommendations.
Participants will be asked to fast for 4 hours prior to the
test and will wear their usual footwear and orthotic
devices, and use their usual assistive devices, if any.
Steady state breath will be determined using the proto-
col outlined by Schwartz.58 Net non-dimensional oxygen
cost (NNcost) will be used to indicate gait efﬁciency as
this has been shown to be the best measure of gait efﬁ-
ciency in children with CP.59 60
Secondary outcome measures
Physical activity
Physical activity will be measured using an accelerometer
(Actigraph wGT3X) worn on the waist above the right
hip or least affected side in the case of signiﬁcant asym-
metry, in the midaxillary line. Participants will be asked
to wear the accelerometer for 7 consecutive days at each
assessment point. Participants with at least 2 days of
monitoring will be included in the analysis as 2 days of
monitoring is necessary to achieve a reliability coefﬁ-
cient of 0.70 for adolescents with CP.61 Time spent in
sedentary, light, moderate-to-vigorous activity will be
determined by classifying accelerometer counts accord-
ing to cut-points validated in children and adolescents
with CP.62 Time in sedentary behaviour as a percentage
of total wear-time and mean accelerometer counts per
minute will also be calculated.
Participation
Participation, deﬁned as ‘involvement in a life situation’
by the WHO’s International Classiﬁcation of
Functioning, Disability and Health (ICF),63 will be
assessed using the Assessment of Life Habits (Life-H)
short form questionnaire V.3.1. The Life-H short form
questionnaire was developed to measure the quality of
social participation in adolescents and adults by drawing
information on the individual’s own perception of their
performance. It contains 77 items divided into 12 life
habit and social role categories. The 12 categories
include nutrition, ﬁtness, personal care, communication,
housing, mobility, responsibilities, interpersonal relation-
ships, community life, education, employment and
recreation. Each domain can be analysed in terms of
level of accomplishment, type of assistance required and
level of satisfaction. Level of accomplishment and level
of satisfaction are scored on a ﬁve-point ordinal con-
tinuum, while level of assistance is attributed a score
based on a four-point scale ranging from no assistance
to human assistance. For scoring purposes, an accom-
plishment score is derived though combination and
weighting of level of difﬁculty and types of assistance
scores and computation of the following: (Σscores×10)/
(number of applicable life habits×9). A higher score is
indicative of greater participation. The Life-H demon-
strated content validity and adequate-to-good levels of
test–retest reliability on initial tool development in ado-
lescents and adults.64 It has also been successfully imple-
mented in cohort studies examining participation levels
of children and adolescents with CP.65 66
Muscle–tendon mechanics
The following muscle–tendon mechanics will be assessed
on the participant’s affected leg in the case of unilateral
CP and the most affected leg in the case of bilateral CP.
If a participant reports that both sides are equally
affected, the right leg will be assessed. Two researchers
blinded to group allocation will conduct the
assessments.
Muscle strength
Plantarﬂexor muscle strength will be assessed on an iso-
kinetic dynamometer (Cybex). For this purpose, partici-
pants will be secured in a seated position with the knee
joint as close to full extension as possible and the foot
secured to the footplate of the dynamometer. The
medial malleolus of the ankle will be aligned with the
centre of rotation of the dynamometer arm. The dyna-
mometer footplate will be positioned as close to perpen-
dicular to the horizontal axis as possible, dependent on
each participant’s available joint range of motion. To
reduce the risk of leg, upper body or heel movement
during contractions, stabilisation straps will be applied
tightly over the foot, thigh and torso, and participants
will be instructed to cross their arms over their chest.
Each participant will be required to push against the
footplate producing a maximal voluntary isometric con-
traction manoeuvre while plantarﬂexor torque is
recorded. To familiarise the participants with the equip-
ment and the plantarﬂexion task, three to ﬁve submaxi-
mal isometric contractions will be performed with the
instruction to ‘rotate the foot away from the body while
keeping the heel in contact with footplate’. These contrac-
tions also provide a task-speciﬁc warm-up to precondition
the tendon and ensure consistency of load-deformation
properties.67 68 After a mandatory 5 min rest period to
minimise fatigue, participants will then perform three
further contractions with maximal effort.
Antagonist muscle activity accompanies agonist muscle
activation during maximal contractions,23 69 which con-
tributes a dorsiﬂexion torque to the plantarﬂexion. As a
result, the net joint torque measured by the dynamom-
eter is an underestimation of the actual torque devel-
oped by the agonist muscle. To account for this
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co-activation, we will ﬁrst measure tibialis anterior
muscle activity using surface electromyography (EMG)
(Delsys) during a slow, submaximal ramped isometric
dorsiﬂexion trial, completed after the ﬁnal plantarﬂex-
ion contractions. Second, an EMG–torque relationship
will be constructed and ﬁtted with a polynomial function
which will then be used to estimate the antagonist
torque present during the plantarﬂexion trials from
EMG amplitude. This torque will be used to quantify
antagonistic co-contraction during the isometric
maximal effort. It will then be added to the net joint
torque measured by the dynamometer to yield the plan-
tarﬂexor torque.
Muscle anatomical cross-sectional area
Three-dimensional (3D) freehand ultrasonography
method will be used to measure muscle volumes, ana-
tomical cross-sectional area (ACSA) and lengths of the
medial and lateral gastrocnemii as well as the soleus
muscle.70 Two-dimensional ultrasound images of the
transverse plane of the muscle with 3D motion data will
be collected using Stradwin software (V.5.1, Mechanical
Engineering, Cambridge University, Cambridge, UK).
Participants will be asked to lie prone on an examin-
ation table with the foot extended off the edge of the
table for 10 min prior to the assessment of muscle size,
to allow ﬂuid shifts in the muscle to stabilise.71 The mid-
point of the line connecting the lateral and medial tibial
plateau and tuberositas calcanei will be marked on the
skin and the distance between these points will be mea-
sured. The starting point of all ultrasound sweeps will be
the line connecting the medial and lateral tibial plateau.
The same starting point of the sweeps and the measured
distance between the tibial plateau and calcanei will
guide the standardisation of muscle length and CSA
analysis. Participants will be instructed to relax their calf
muscles during the imaging. A strap will be placed over
the participant’s thighs just above the knee and a
researcher will apply a gentle pressure on the heel in
order to avoid any movement of the limbs. Hip and
knee joints will be fully extended, unless full joint exten-
sion is not possible, in which case the degree of joint
extension will be measured with a goniometer and kept
identical during the postmeasurements and follow-up
measurements. During the assessment, the foot will be
extended off the edge of the examination table, com-
pletely relaxed and the ankle joint will be in its resting
position. Either single or multiple sweeps (depending
on the size of the muscle) will be taken by moving the
probe across the calf while the position of the four
markers attached to the probe will be tracked by a pos-
ition sensor system. A consistent, minimal pressure will
be applied with the probe to avoid compression of the
muscle, aided by the application of a transmission gel to
improve acoustic coupling. In order to keep the pressure
minimal and avoid dark ‘gaps’ of the lateral edges of the
image (probe width=6 cm), a customised curved gel pad
will be held in between the skin and the probe’s
imaging surface. The probe will be kept perpendicular
to the surface curvature of the shank (ie, muscle). A
reconstruction of volume, anatomical cross-sectional
area and length measurements will be performed using
the Stradwin software (ﬁgure 2). Anatomical cross-
sectional area will be measured from muscle regions cor-
responding to each muscle’s maximum anatomical cross-
sectional area. The location of the maximum ACSA for
normally developed adults has been reported to be at
67%, 81% and 84% of the shank length (measured
from the tuberositas calcanei to the tibial plateau) for
the soleus, medial and lateral gastrocnemius, respect-
ively.72 The location of the maximum CSA in adoles-
cents with CP is not known and the possibility of a
region-speciﬁc hypertrophy in response to resistance
training cannot be excluded. However, for the standard-
isation purposes, we will measure the CSA at the same
locations of all participants recommended for normally
developed adults,72 but will also report the location of
the true maximal ACSA and its interindividual variation.
Tendon cross-sectional area
Achilles tendon cross-sectional area will be obtained using
a modiﬁed silicon ultrasound gel pad (Aquaﬂex 2×9 cm,
Parker Labs) to take three discrete ultrasound images of
the Achilles tendon cross-sectional area, ∼40 mm proxim-
ally to the tendon insertion.23 The tendon perimeter will
then be traced using specialist software (Esaote, Italy;
ﬁgure 3), and the image with the smallest cross-sectional
area will be used for further analysis.
Muscle and tendon force
Plantarﬂexor torque will also be obtained during passive
isolated ankle rotations based on previous methods73 74
in order to estimate medial gastrocnemius muscle force.
Brieﬂy, the ankle will be rotated at a constant angular
velocity of 10°/s through maximum plantarﬂexion and
dorsiﬂexion. To do this, the participant’s available range
of motion will initially be determined by manually
moving the foot into dorsiﬂexion and plantarﬂexion.
Ultrasonography will be used to track movement of the
muscle–tendon junction of the medial gastrocnemius
muscle throughout the passive stretch. Achilles tendon
moment arm will then be obtained using the tendon
excursion method.21 The moment arm, deﬁned as the
shortest perpendicular distance between the joint centre
of rotation and the line of the Achilles tendon force, will
be determined by ﬁtting a polynomial function between
tendon displacement and ankle rotation data obtained
from the isokinetic dynamometer.21 The moment arm
will then be calculated using the formula below:
r = Dd/Du ð1Þ
where r is the Achilles tendon moment arm (m), Δd
represents tendon excursion (m) and Δθ is the change
in joint angle (rad).
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Maximal plantarﬂexor torque measured during
maximal voluntary contractions will be divided by
Achilles tendon moment arm to give an estimate of
Achilles tendon force using the equation below:
FT ¼ T=r ð2Þ
where FT is the tendon force and T is the ankle torque
as measured from the isokinetic dynamometer and cor-
rected for antagonist activation torque as described
above.
Since muscle force cannot be measured in vivo, the
contribution of the medial gastrocnemius muscle to
passive ankle joint torque will be estimated. To do this,
passive torque will be measured during the passive rota-
tions, and divided by Achilles tendon moment arm (as
described above) to give an estimate of total muscle
force. The force contribution from the medial gastro-
cnemius muscle will then be estimated using the
formula below:
FMG ¼ SMG  FTotal ð3Þ
where FMG is the medial gastrocnemius muscle force
(N), FTotal is total muscle force and SMG is a scaling
factor representing the medial gastrocnemius’ contribu-
tion to the total muscle force. This scaling factor will be
based on the medial gastrocnemius’ anatomical cross-
sectional area relative to the total triceps surae cross-
sectional area.
Muscle and tendon length
The lengths of the medial gastrocnemius muscle and
Achilles tendon will be measured, using a combination of
ultrasound (Echoblaster 128, Telemed, Vilnius, Lithuania)
Figure 3 Measurement of Achilles tendon cross-sectional
area. Area outlined in red represents the cross-section of the
Achilles tendon. The silicon boundary shown on the image is
formed by the silicon gel pad that is placed in between the
ultrasound probe and the skin surface.
Figure 2 Three-dimensional
freehand ultrasound method for
the assessment of muscle
volume and ACSA. A segmented
and rendered medial
gastrocnemius volume of a
12-year boy with a CP, GMFCS
level II, moderate muscle atrophy.
Three parallel transverse sections
of the reconstructed muscle
volume are depicted. The same
transverse sections (2D B-mode
images) with outlined ACSA of
MG (white dotted line) are shown
from proximal and distal regions
of the muscle, respectively. The
B-mode scans were acquired with
a modified curved gel pad with a
probe length of 60 mm and with a
single sweep. The B-mode slice
thickness for the 3D muscle
model reconstruction was set to
5 mm. 3D, three-dimensional;
MG, medial gastrocnemius.
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and motion analysis data (Motion Analysis, Santa Rosa,
California, USA). For this purpose, reﬂective markers will
be placed on the medial epicondyle of the femur, the
Achilles tendon insertion and on the ultrasound probe.
Ultrasound images will be manually digitised to identify
the medial gastrocnemius muscle–tendon junction in
each video frame (V.9, Vicon, Oxford, UK). The position
of the muscle–tendon junction in the global coordinate
system of the motion analysis system will then be calculated
by combining coordinates from the ultrasound probe,
with local muscle–tendon junction coordinates from the
ultrasound image. Using custom written analysis software
(Matlab, MathWorks, Natick, Massachusetts, USA), the
medial gastrocnemius muscle length will be calculated as
the linear distance from the medial epicondyle marker to
the global muscle–tendon junction position. Similarly, the
Achilles tendon length will be calculated as the linear dis-
tance between the muscle–tendon junction and the calca-
neal insertion (ﬁgure 4). The slack lengths of muscle and
tendon will be calculated as the lengths at which there is a
sustained increase in ankle torque above zero (baseline +2
SDs),34 75 and thus, where slack has been taken up.
Muscle and tendon stiffness
Achilles tendon stiffness will be calculated as the change
in Achilles tendon force (measured from maximal
voluntary contraction manoeuvres), divided by the
corresponding change in Achilles tendon length in the
linear portion of the force–length relationship
(ﬁgure 5):
kT ¼ DFT=DLT ð4Þ
where kT is tendon stiffness, ΔFT is change in tendon
force and ΔLT is change in tendon length. An estimate
of medial gastrocnemius muscle stiffness will also be
derived from the data by dividing the medial gastrocne-
mius force (measured from passive rotations man-
oeuvres) by elongation of the medial gastrocnemius
muscle:
kMG ¼DFMG=DLMG ð5Þ
where kMG is medial gastrocnemius muscle stiffness,
ΔFMG is change in medial gastrocnemius force; ΔLMG is
change in medial gastrocnemius length.
Young’s modulus
The tendon’s Young’s modulus will be calculated by
multiplying tendon stiffness by tendon resting length
and dividing by tendon cross-sectional area:
Young0s modulus
¼
tendon stiffness  tendon resting length
tendon cross - sectional area
ð6Þ
Muscle, tendon and fascicle strain
Medial gastrocnemius muscle and Achilles tendon
strains will be calculated by dividing muscle and tendon
displacement during the passive ankle rotations, by the
corresponding resting lengths. Similarly, muscle fascicle
strain will be calculated by dividing muscle fascicle dis-
placement during the passive ankle rotations by muscle
fascicle length at rest. The ultrasound probe will be
placed over the muscle belly revealing fascicles lying
between deep and superﬁcial aponeuroses of the medial
gastrocnemius muscle. We will track the elongation of
three muscle fascicles during the passive dorsiﬂexion
trials using open source digital measurement software
(Image J, National Institutes of Health (NIH)). Fascicle
length will be estimated as the distance between the
insertions on the deep and superﬁcial aponeuroses.
Length measurements will be averaged across the three
fascicles, which will be used for subsequent analyses.
Treadmill walking
Participants will be asked to walk on a fully instrumented
treadmill (Bertec Corporation, Columbus, Ohio, USA)
at their preferred walking speed as previously
described.76 Prior to testing, participants will perform a
familiarisation session to ensure they are comfortable
walking on the treadmill, and to establish a comfortable
preferred walking speed. During the walking trials, parti-
cipants will be barefoot and instructed to hold onto the
handrail to maintain balance if required. Participants
Figure 4 Experimental setup for measuring muscle length
and TL. Achilles tendon length is measured as the distance
from the MTJ to the calcaneus, and gastrocnemius muscle
length as the distance from the mid-point of the femoral
epicondyles to the MTJ. MTJ, muscle–tendon junction; TL,
tendon length.
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will begin by walking at a relatively slow speed and tread-
mill speed will slowly increase until the participant
reports the current speed is faster than their preferred
speed. The treadmill speed will then be slowly decreased
until the participant reports the current speed to be
slower than preferred. This procedure will be repeated
three times and the average of the three ‘faster’ and
three ‘slower’ than preferred speeds will be taken as the
participants preferred walking speed.76 This procedure
also allows for treadmill familiarisation and participant
warm-up. Following a mandatory 2 min rest period after
familiarisation, participants will be asked to walk on the
treadmill at their preferred walking speed for 2 min to
ensure an adequate number of gait cycles are
collected.77
During the walking trials, an ultrasound probe will
be placed over the muscle–tendon junction of the
medial gastrocnemius muscle and Achilles tendon.
Three-dimensional motion analysis and ultrasound data
will be combined to quantify muscle and tendon length
changes as described above (see ‘Muscle–tendon length’
section). A second ultrasound probe will be placed over
the muscle belly of the medial gastrocnemius to visualise
movement of the muscle fascicles.
Gait kinematics
Knee, ankle and hip joint kinematics will be measured
from a full body motion analysis marker set. For this
purpose, reﬂective markers will be placed on the fore-
head and proximal sternum and then bilaterally at the
distal end of each clavicle, anterior superior iliac spine,
sacrum, the greater trochanters, mid-thigh, medial and
lateral femoral epicondyles, on each tibia (midway
between the ankle and knee), the medial and lateral
malleoli, the heads of the ﬁrst and ﬁfth metatarsals and
the calcaneus. The change in ankle and knee ﬂexion
angles during the stance phase will be used as the
primary indicator of changes in gait kinematics.
Gross motor function
Participants’ gross motor function will be assessed using
dimensions D and E of the Gross Motor Function
Measure (GMFM-66) and self-selected walking speed.
The GMFM-66 is a valid, reliable and responsive
measure of change in gross motor function over time in
children with CP.78 79 Dimension D evaluates activities in
standing. Dimension E evaluates activities in walking,
running and jumping. Participants’ performance of
dimensions D and E of the GMFM-66 will be video
recorded and scored by a physiotherapist blinded to
group allocation. The scores recorded for each dimen-
sion will be expressed as a percentage of the total pos-
sible score. A higher score indicates better gross motor
function.
Participants’ self-selected walking speed will be calcu-
lated using the time they take to walk 10 m over ground
measured by a blinded assessor. Participants will walk
∼2 m up to the start point of a 10 m walkway and con-
tinue to walk for ∼2 m after the stop point of the 10 m
walkway. Participants will not be told where the start and
stop points are. Participants will complete this three
times and the average speed of the three trials will be
used in analysis.
Process evaluation
A mixed-methods process evaluation will be conducted
in order to assess the feasibility and acceptability of the
intervention. Fidelity to the intervention delivery and
uptake will be assessed to identify explanatory factors
relating to potential discrepancies between the expected
Figure 5 Ultrasound images
visualising the displacement of
the muscle–tendon junction
during an isometric muscle
contraction at rest (A), mid
contraction (B) and at maximal
force (C). Muscle–tendon junction
displacement is plotted against
the corresponding force to
produce a force-elongation graph.
Tendon stiffness is measured as
the slope of the force-elongation
curve.
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and observed outcome. Data will be gathered from
various sources.
Attendance and compliance to the intervention will
be monitored by the physiotherapist delivering the
supervised session. During each session, the physiother-
apist will record details of the warm-up, cool-down and
stretches, the type of exercises that were completed, the
number of repetitions and sets of each exercise that
were completed, the type of resistance and load that was
added to each exercise, how each exercise was pro-
gressed, and details of the home exercise(s) prescribed.
In order to monitor compliance with the home exercise
programme and adverse events, participants will record
their adherence to the home exercise programme and
any potentially related or unrelated adverse events
during home sessions using the patient support tool or
paper exercise diary. Information from the patient
support tool will be transmitted directly to the research
team.
Fidelity of the resistance training programme to trial
protocol will be quantiﬁed by observations of four ses-
sions (two home sessions and two group sessions) for
each participant during the 10-week period using a proto-
col checklist. A member of the research team will record
the quantity and quality of exercises. The number of
repetitions and sets performed of each exercise, and the
amount of resistance added to each exercise will be
recorded. It will be noted if the exercise was progressed
based on individual strength capacity. The calf muscle
will be palpated during each exercise to determine if it is
being activated. Aspects of the quality of the exercise
(ankle range of motion that the exercise is performed
through, performance of prescribed repetitions to
fatigue, movement quality and degree of knee extension
maintained during the exercise) will be rated on a four-
point scale, where a higher score indicates better quality.
To determine the feasibility and acceptability of the
intervention, semistructured exit interviews will be con-
ducted with all participants in the resistance training
group within 1 week of completion of the intervention.
Participants will be asked to reﬂect on their experience,
including any positive or challenging aspects of taking
part in the programme, to help identify factors which
may impact on adherence. Semistructured interviews
will also be conducted with physiotherapists at the end
of their involvement in the study to explore their experi-
ences of delivering the resistance training programme
and identify facilitators and challenges to the delivery of
the intervention per protocol and potential implementa-
tion into future practice. Indicative topic guides for the
semistructured interviews with adolescents who partici-
pate in physiotherapists who deliver the progressive
resistance training programme are available in online
supplementary ﬁles 5 and 6, respectively.
Semistructured interviews will be transcribed verbatim,
and checked against the original recordings. Data will
be analysed using a multistage process (familiarisation,
indexing and sorting, developing an initial framework,
applying the framework, charting the data, interpret-
ation) described in the framework approach.80 81 Key
issues arising from the data in relation to study aims and
the literature will develop the a priori thematic frame-
work both deductively and inductively. This framework
will then be applied to the text prior to charting into
the framework matrix and interpretation of data.
Associations and differences in the data will be sought to
enhance the understanding of the participants’ experi-
ence of taking part in and physiotherapists’ experiences
of delivering resistance training.
Data analysis
To evaluate the effect of resistance training of the ankle
plantarﬂexors on gait efﬁciency, activity and participa-
tion (aim 1), and muscle–tendon mechanics (aim 2)
among adolescents with CP, general linear models will
be used to evaluate differences in continuous data
between the resistance training and usual care control
group at 10 and 22 weeks, respectively. The principal
analysis will be on an intention-to-treat basis. Subgroup
analysis will be conducted according to: (1) the partici-
pants’ ability to plantarﬂex the ankle, that is, rated as
‘normal’, ‘impaired’ and ‘no active movement’; (2)
adherence categorised as ≥70% or <70% of the total
dose (30 sessions). Statistical analyses will be conducted
using IBM SPSS Statistics for Windows (V.22.0, IBM
Corp, Amonk, New York, USA). Statistical signiﬁcance
will be set at α=0.05.
Sample size
The sample size calculation was based on being able to
show a minimal detectable difference in the primary
outcome, NNcost, between the two groups. The calcula-
tion was based on an analysis of covariance approach,
whereby the NNcost values at follow-up are considered
the outcome variable, and the NNcost values at baseline
are used as a covariate. Both the minimal detectable dif-
ference of 0.17 and SD of 0.31 were based on values
from the literature.60 A correlation of 0.70 between base-
line and follow-up NNcost values was assumed. Using a
5% signiﬁcance level and 80% power, it is calculated
that a sample size of 27 participants in each group is
required. It is estimated that there will be a drop-out of
10%, and thus it is proposed to recruit 30 people per
group into the study, 60 people in total.
ETHICS AND DISSEMINATION
The trial is sponsored by Brunel University London. A
parent or legal guardian of participants under 16 years
and participants over 16 years will provide written
informed consent. Participants under 16 years will
provide written or verbal assent. All participants will take
part on a voluntary basis and will be informed that they
can withdraw at any time without this inﬂuencing their
subsequent treatment. The trial will comply with the
latest Declaration of Helsinki. Data will be kept secure
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and conﬁdential in line with the data management
plan (doi: 10.17633/rd.brunel.3485234). Pseudonymised
quantitative participant data will made available in a
public repository following publication of data.
The Trial Steering Committee (TSC) will monitor and
supervise the progress of the trial towards its interim and
overall objectives. The membership of the TSC consists of
an independent Chair person, who is not involved dir-
ectly with the study, a representative from the funder of
the study, two independent expert members and the
chief investigator. All adverse events will be reported to
the TSC. Serious adverse events will be reported to the
trial sponsor within 24 hours of a member of the research
team becoming aware of it. Unexpected, related serious
adverse events will be reported to the Research Ethics
Committee within 15 days of a member of the research
team becoming aware of the event.
The ﬁndings of the trial will be distributed widely to
academic and non-academic audiences. The results will
be published in academic journals and presented at
national and international conferences. Summaries of
the results will also be developed and distributed to ado-
lescents with CP, their families and healthcare profes-
sionals through the media, professional groups and
charitable organisations. The research team will work
with the TSC and the STAR advisory group, which con-
sists of young people with and without CP, to ensure that
these summaries are accessible to the target audience
and that the results are disseminated through appropri-
ate channels.
Author affiliations
1College of Health and Life Sciences, Brunel University London, London, UK
2School of Sport, Health and Applied Science, St. Mary’s University,
Twickenham, UK
3Department of Physical Therapy, University of British Columbia, Vancouver,
British Columbia, Canada
4One Small Step Gait Laboratory, Guy’s Hospital, Guy’s and St. Thomas’ NHS
Foundation Trust, London, UK
5Department of Physiotherapy, Royal Free London NHS Foundation Trust,
Swiss Cottage School Development and Research Centre, London, UK
Contributors JMR and NT drafted the protocol and coordinated all
subsequent revisions. JMR is the chief investigator for the trial. All authors
were involved in the design of the study and the protocol development. All
authors have read and approved the final draft of the protocol.
Funding Action Medical Research and the Chartered Society of Physiotherapy
Charitable Trust have jointly funded this project, and it is supported by a
generous grant from The Henry Smith Charity (GN2340).
Competing interests None declared.
Ethics approval This registered trial (ISRCTN90378161) has ethical approval
from Brunel University London’s Department of Clinical Sciences’ Research
Ethics Committee and the National Research Ethics Service (NRES)
Committee London—Surrey Borders.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Strauss D, Brooks J, Rosenbloom L, et al. Life expectancy in
cerebral palsy. An update. Dev Med Child Neurol 2008;50:487–93.
2. Day SM, Wu YW, Strauss DJ, et al. Change in ambulatory ability of
adolescents and young adults with cerebral palsy. Dev Med Child
Neurol 2007;49:647–53.
3. Opheim A, Jahnsen R, Olsson E, et al. Walking function, pain, and
fatigue in adults with cerebral palsy: a 7-year follow-up study. Dev
Med Child Neurol 2009;51:381–8.
4. Bottos M, Feliciangeli A, Sciuto L, et al. Functional status of adults
with cerebral palsy and implications for treatment of children. Dev
Med Child Neurol 2001;43:516–28.
5. Ryan JM, Crowley VE, Hensey O, et al. Habitual physical activity
and cardiometabolic risk factors in adults with cerebral palsy. Res
Dev Disabil 2014;35:1995–2002.
6. Nieuwenhuijsen C, van der Slot WM, Beelen A, et al. Inactive
lifestyle in adults with bilateral spastic cerebral palsy. J Rehabil Med
2009;41:375–81.
7. Strauss D, Cable W, Shavelle R. Causes of excess mortality in
cerebral palsy. Dev Med Child Neurol 1999;41:580–5.
8. Ryan JM, Hensey O, McLoughlin B, et al. Reduced
moderate-to-vigorous physical activity and increased sedentary
behavior is associated with elevated blood pressure values in
children with cerebral palsy. Phys Ther 2014;94:1143–53.
9. Peterson MD, Ryan J, Hurvitz EA, et al. Chronic conditions in adults
with cerebral palsy. JAMA 2015;314:2303–5.
10. Waters RL, Mulroy S. The energy expenditure of normal and
pathologic gait. Gait Posture 1999;9:207–31.
11. Unnithan VB, Clifford C, Bar-Or O. Evaluation by exercise testing of
the child with cerebral palsy. Sports Med 1998;26:239–51.
12. Brehm MA, Becher J, Harlaar J. Reproducibility evaluation of gross
and net walking efficiency in children with cerebral palsy. Dev Med
Child Neurol 2007;49:45–8.
13. Dallmeijer AJ, Brehm MA. Physical strain of comfortable walking in
children with mild cerebral palsy. Disabil Rehabil 2011;33:1351–7.
14. Maltais DB, Pierrynowski MR, Galea VA, et al. Physical activity level
is associated with the O2 cost of walking in cerebral palsy. Med Sci
Sports Exerc 2005;37:347–53.
15. Kerr C, Parkes J, Stevenson M, et al. Energy efficiency in gait,
activity, participation, and health status in children with cerebral
palsy. Dev Med Child Neurol 2008;50:204–10.
16. Kerr C, McDowell BC, Parkes J, et al. Age-related changes in
energy efficiency of gait, activity, and participation in children with
cerebral palsy. Dev Med Child Neurol 2011;53:61–7.
17. Unnithan VB, Dowling JJ, Frost G, et al. Cocontraction and phasic
activity during GAIT in children with cerebral palsy. Electromyogr
Clin Neurophysiol 1996;36:487–94.
18. Stackhouse SK, Binder-Macleod SA, Lee SC. Voluntary muscle
activation, contractile properties, and fatigability in children with and
without cerebral palsy. Muscle Nerve 2005;31:594–601.
19. Tedroff K, Knutson LM, Soderberg GL. Co-activity during maximum
voluntary contraction: a study of four lower-extremity muscles in
children with and without cerebral palsy. Dev Med Child Neurol
2008;50:377–81.
20. Unnithan VB, Dowling JJ, Frost G, et al. Role of cocontraction in the
O2 cost of walking in children with cerebral palsy. Med Sci Sports
Exerc 1996;28:1498–504.
21. Ozmun JC, Mikesky AE, Surburg PR. Neuromuscular adaptations
following prepubescent strength training. Med Sci Sports Exerc
1994;26:510–14.
22. Ramsay JA, Blimkie CJ, Smith K, et al. Strength training effects in
prepubescent boys. Med Sci Sports Exerc 1990;22:605–14.
23. Hakkinen K, Komi PV. Electromyographic changes during strength
training and detraining. Med Sci Sports Exerc 1983;15:455–60.
24. Reid S, Hamer P, Alderson J, et al. Neuromuscular adaptations to
eccentric strength training in children and adolescents with cerebral
palsy. Dev Med Child Neurol 2010;52:358–63.
25. Cronin NJ, Peltonen J, Sinkjaer T, et al. Neural compensation within
the human triceps surae during prolonged walking. J Neurophysiol
2011;105:548–53.
26. Farris DJ, Sawicki GS. Human medial gastrocnemius force-velocity
behavior shifts with locomotion speed and gait. Proc Natl Acad Sci
USA 2012;109:977–82.
27. Lichtwark GA, Bougoulias K, Wilson AM. Muscle fascicle and series
elastic element length changes along the length of the human
gastrocnemius during walking and running. J Biomech 2007;40:157–64.
28. Ishikawa M, Komi PV, Grey MJ, et al. Muscle-tendon interaction and
elastic energy usage in human walking. J Appl Physiol
2005;99:603–8.
29. Fukunaga T, Kubo K, Kawakami Y, et al. In vivo behaviour of human
muscle tendon during walking. Proc Biol Sci 2001;268:229–33.
12 Ryan JM, et al. BMJ Open 2016;6:e012839. doi:10.1136/bmjopen-2016-012839
Open Access
group.bmj.com on October 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
30. Barber L, Carty C, Modenese L, et al. Lower limb muscle fascicle
function during gait in children with cerebral palsy. ISB 2015, 25th
Congress of the International Society of Biomechanics.
31. Kalsi G, Fry N, Shortland A. Gastrocnemius muscle-tendon
interaction during walking in typically-developing adults and children,
and in children with spastic cerebral palsy. J Biomech 2016. [Epub
ahead of print 8 Aug 2016].
32. Ryschon TW, Fowler MD, Wysong RE, et al. Efficiency of human
skeletal muscle in vivo: comparison of isometric, concentric, and
eccentric muscle action. J Appl Physiol 1997;83:867–74.
33. Theis N, Mohageghi A, Korff T. Mechanical and material properties of
the triceps surae muscles and Achilles tendon in children with spastic
cerebral palsy and typically developing children. J Biomech 2016.
[Epub ahead of print 26 Jul 2016].
34. Barber L, Barrett R, Lichtwark G. Medial gastrocnemius muscle
fascicle active torque-length and Achilles tendon properties in young
adults with spastic cerebral palsy. J Biomech 2012;45:2526–30.
35. Waugh CM, Korff T, Fath F, et al. Effects of resistance training on
tendon mechanical properties and rapid force production in
prepubertal children. J Appl Physiol 2014;117:257–66.
36. Shortland A. Muscle deficits in cerebral palsy and early loss of
mobility: can we learn something from our elders? Dev Med Child
Neurol 2009;51(Suppl 4):59–63.
37. Artero EG, Lee DC, Lavie CJ, et al. Effects of muscular strength on
cardiovascular risk factors and prognosis. J Cardiopulm Rehabil
Prev 2012;32:351–8.
38. Peterson MD, Gordon PM, Hurvitz EA. Chronic disease risk among
adults with cerebral palsy: the role of premature sarcopoenia, obesity
and sedentary behaviour. Obes Rev 2013;14:171–82.
39. Verschuren O, Ada L, Maltais DB, et al. Muscle strengthening in
children and adolescents with spastic cerebral palsy: considerations for
future resistance training protocols. Phys Ther 2011;91:1130–9.
40. Damiano DL. Progressive resistance exercise increases strength but
does not improve objective measures of mobility in young people
with cerebral palsy. J Physiother 2014;60:58.
41. Scianni A, Butler JM, Ada L, et al. Muscle strengthening is not
effective in children and adolescents with cerebral palsy: a
systematic review. Aust J Physiother 2009;55:81–7.
42. Park EY, Kim WH. Meta-analysis of the effect of strengthening
interventions in individuals with cerebral palsy. Res Dev Disabil
2014;35:239–49.
43. Taylor NF, Dodd KJ, Baker RJ, et al. Progressive resistance training
and mobility-related function in young people with cerebral palsy: a
randomized controlled trial. Dev Med Child Neurol 2013;55:806–12.
44. Faigenbaum AD, Kraemer WJ, Blimkie CJ, et al. Youth resistance
training: updated position statement paper from the National
Strength and Conditioning Association. J Strength Cond Res
2009;23(5 Suppl):S60–79.
45. Scholtes VA, Becher JG, Comuth A, et al. Effectiveness of functional
progressive resistance exercise strength training on muscle strength
and mobility in children with cerebral palsy: a randomized controlled
trial. Dev Med Child Neurol 2010;52:e107–13.
46. Eek MN, Beckung E. Walking ability is related to muscle strength in
children with cerebral palsy. Gait Posture 2008;28:366–71.
47. Noble JJ, Fry NR, Lewis AP, et al. Lower limb muscle volumes in
bilateral spastic cerebral palsy. Brain Dev 2014;36:294–300.
48. Ross SA, Engsberg JR. Relationships between spasticity, strength,
gait, and the GMFM-66 in persons with spastic diplegia cerebral
palsy. Arch Phys Med Rehabil 2007;88:1114–20.
49. Ferland C, Lepage C, Moffet H, et al. Relationships between lower
limb muscle strength and locomotor capacity in children and
adolescents with cerebral palsy who walk independently. Phys
Occup Ther Pediatr 2012;32:320–32.
50. McNee AE, Gough M, Morrissey MC, et al. Increases in muscle
volume after plantarflexor strength training in children with spastic
cerebral palsy. Dev Med Child Neurol 2009;51:429–35.
51. Engsberg JR, Ross SA, Collins DR. Increasing ankle strength to
improve gait and function in children with cerebral palsy: a pilot
study. Pediatr Phys Ther 2006;18:266–5.
52. Craig P, Dieppe P, Macintyre S, et al. Medical Research Council
Guidance: developing and evaluating complex interventions: the new
medical research council guidance. BMJ 2008;337:a1655.
53. Palisano RJ, Rosenbaum P, Bartlett D, et al. Content validity of the
expanded and revised Gross Motor Function Classification System.
Dev Med Child Neurol 2008;50:744–50.
54. Fowler EG, Staudt LA, Greenberg MB, et al. Selective Control
Assessment of the Lower Extremity (SCALE): development,
validation, and interrater reliability of a clinical tool for patients with
cerebral palsy. Dev Med Child Neurol 2009;51:607–14.
55. Contreras B. Bodyweight strength training anatomy. Champaign, IL:
Human Kinetics, 2013:160–1.
56. Arampatzis A, Karamanidis K, Stafilidis S, et al. Effect of different
ankle- and knee-joint positions on gastrocnemius medialis fascicle
length and EMG activity during isometric plantar flexion. J Biomech
2006;39:1891–902.
57. Hébert-Losier K, Holmberg HC. Knee angle-specific MVIC for triceps
surae EMG signal normalization in weight and non weight-bearing
conditions. J Electromyogr Kinesiol 2013;23:916–23.
58. Schwartz MH. Protocol changes can improve the reliability of net
oxygen cost data. Gait Posture 2007;26:494–500.
59. Schwartz MH, Koop SE, Bourke JL, et al. A nondimensional
normalization scheme for oxygen utilization data. Gait Posture
2006;24:14–22.
60. Thomas SS, Buckon CE, Schwartz MH, et al. Walking
energy expenditure in able-bodied individuals: a comparison of
common measures of energy efficiency. Gait Posture
2009;29:592–6.
61. Mitchell LE, Ziviani J, Boyd RN. Variability in measuring physical
activity in children with cerebral palsy. Med Sci Sports Exerc
2014;47:194–200.
62. Trost S, Fragala-Pinkham M, Lennon N, et al. Decision trees for
detection of activity intensity in youth with cerebral palsy. Med Sci
Sports Exerc 2015;48:958–66.
63. World Health Organisation. International Classification of
Functioning, Disability and Health: ICF. Geneva: World Health
Organisation, 2001.
64. Fougeyrollas P, Noreau L, Bergeron H, et al. Social consequences
of long term impairments and disabilities: conceptual approach and
assessment of handicap. Int J Rehabil Res 1998;21:127–41.
65. Calley A, Williams S, Reid S, et al. A comparison of activity,
participation and quality of life in children with and without spastic
diplegia cerebral palsy. Disabil Rehabil 2012;34:1306–10.
66. Dang VM, Colver A, Dickinson HO, et al. Predictors of participation
of adolescents with cerebral palsy: a European multi-centre
longitudinal study. Res Dev Disabil 2014;36c:551–64.
67. Rigby BJ, Hirai N, Spikes JD, et al. The mechanical properties of rat
tail tendon. J Gen Physiol 1959;43:265–83.
68. Maganaris CN, Paul JP. In vivo human tendon mechanical
properties. J Physiol (Lond) 1999;521(Pt 1):307–13.
69. Damiano DL, Martellotta TL, Sullivan DJ, et al. Muscle force
production and functional performance in spastic cerebral palsy:
relationship of co-contraction. Arch Phys Med Rehabil
2000;81:895–900.
70. Barber L, Barrett R, Lichtwark G. Validation of a freehand 3D
ultrasound system for morphological measures of the medial
gastrocnemius muscle. J Biomech 2009;42:1313–19.
71. Cerniglia LM, Delmonico MJ, Lindle R, et al. Effects of acute supine
rest on mid-thigh cross-sectional area as measured by computed
tomography. Clin Physiol Funct Imaging 2007;27:249–53.
72. Mersmann F, Bohm S, Schroll A, et al. Validation of a simplified
method for muscle volume assessment. J Biomech
2014;47:1348–52.
73. Theis N, Mohagheghi AA, Korff T. Method and strain rate
dependence of Achilles tendon stiffness. J Electromyogr Kinesiol
2012;22:947–53.
74. Kay AD, Husbands-Beasley J, Blazevich AJ. Effects of contract-
relax, static stretching, and isometric contractions on muscle-tendon
mechanics. Med Sci Sports Exerc 2015;47:2181–90.
75. Hoang PD, Herbert RD, Todd G, et al. Passive mechanical
properties of human gastrocnemius muscle–tendon units, muscle
fascicles and tendons in vivo. J Exp Biol 2007;210:4159–68.
76. Dingwell JB, Marin LC. Kinematic variability and local dynamic
stability of upper body motions when walking at different speeds.
J Biomech 2006;39:444–52.
77. Galna B, Lord S, Rochester L. Is gait variability reliable in older
adults and Parkinson’s disease? Towards an optimal testing
protocol. Gait Posture 2013;37:580–5.
78. Nordmark E, Hagglund G, Jarnlo GB. Reliability of the gross motor
function measure in cerebral palsy. Scand J Rehabil Med
1997;29:25–8.
79. Russell DJ, Rosenbaum PL, Cadman DT, et al. The gross motor
function measure: a means to evaluate the effects of physical
therapy. Dev Med Child Neurol 1989;31:341–52.
80. Ritchie J, Lewis J. Qualitative research practice: a guide for social
science students and researchers. London: Sage, 2003.
81. Gale NK, Heath G, Cameron E, et al. Using the framework method
for the analysis of qualitative data in multi-disciplinary health
research. BMC Med Res Methodol 2013;13:117.
Ryan JM, et al. BMJ Open 2016;6:e012839. doi:10.1136/bmjopen-2016-012839 13
Open Access
group.bmj.com on October 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
cerebral palsy
resistance training for adolescents with
feasibility, acceptability and efficacy of 
randomised controlled trial to determine the
cerebral palsy (STAR): study protocol of a 
Strength Training for Adolescents with
Levin and Thomas Korff
WendyCharlie Waugh, Adam Shortland, Grace Lavelle, Marika Noorkoiv, 
Jennifer M Ryan, Nicola Theis, Cherry Kilbride, Vasilios Baltzopoulos,
doi: 10.1136/bmjopen-2016-012839
2016 6: BMJ Open 
 http://bmjopen.bmj.com/content/6/10/e012839
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/6/10/e012839
This article cites 75 articles, 10 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (315)Rehabilitation medicine
 (649)Paediatrics
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on October 10, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
